IsoRay, Inc.

IsoRay Medical™ utilizes proprietary technologies to deliver novel brachytherapy approaches to clinicians. IsoRay’s Cesium-131 isotope has been used as primary treatment for prostate cancer in over 7,000 patients. As adjuvant radiation therapy, Cesium-131 is being employed in the management of non-small cell lung cancer, intra-cranial tumors (including meningiomas), and head & neck malignancies post-surgical resection.

Services Provided:

  • Introduced company to our broker/fund network via in-house marketing reps at $.40/share averaging 35K shares daily traded.
  • Initiated targeted IR campaign with Corporate Profile & Investment Highlights to our network of opt-in subscribers.
  • Stimulated financial community through creative content, research reports and industry publications.
  • Opened new channels of Social & Digital Media exposure previously non-existent.
  • Proactively reached out to Institutions & contacted Analysts for coverage consideration.


  • After 90 days, the 20d average volume increased to 500K shares from 35K shares, share price at the time, reached a record high of $1.60/share.
  • Featured articles appear in Seeking Alpha, The Stock Pickr (The Motley Fool publication) and various other trade journals.
  • After a year, the company gained 2 new analysts and a 30% increase in institutional ownership, including 3 funds positioning over a million shares each.
  • Shortly thereafter, company announces significant Brain tumor treatment results, stock soars to record high of $3.77 on 112 million shares traded.
  • National & International Press, market exposure & investor interest increase rapidly.
  • Over the next two years, company raises over $20mm in equity financings.

More Client Stories

CEO, Payment Data Systems

Louis Hoch
CEO, Sonoma Pharmaceuticals

Jim Schutz
Former CEO, IsoRay

Dwight Babcock

We help you market your investment story with maximum impact and deliver your corporate message effectively

Contact Us
or call
+1 954 360 9998